NCT03527238View on ClinicalTrials.gov

Optimizing Immunosuppression Drug Dosing Via Phenotypic Precision Medicine

PHASE2CompletedINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

September 21, 2018

Primary Completion Date

June 2, 2020

Study Completion Date

August 31, 2021

Conditions
Liver TransplantKidney Transplant
Interventions
OTHER

PPM-based Computation Assisted Drug Dosing

Tacrolimus dosing based on application of PPM.

DRUG

Tacrolimus

Dosing of calcineurin inhibitor, tacrolimus

Trial Locations (3)

32610

UF Health at the University of Florida, Gainesville

90095

UCLA, Los Angeles

119077

National University of Singapore, Singapore

All Listed Sponsors
collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

University of Florida

OTHER

NCT03527238 - Optimizing Immunosuppression Drug Dosing Via Phenotypic Precision Medicine | Biotech Hunter | Biotech Hunter